Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from NKGen Biotech ( (NKGN) ).
On January 30, 2026, NKGen Biotech, Inc. and its affiliate NKGen Operating Biotech, Inc. entered into a third amendment to an existing secured promissory note with AlpineBrook Capital GP I Limited, securing an additional $251,000 in funding. The amendment increases the note’s total principal to $26,758,106 and specifies that interest on this latest tranche, termed the Fourth Additional New Loan, began accruing from the funding date of January 30, 2026, further expanding the company’s available debt financing and potentially supporting its near-term liquidity needs.
More about NKGen Biotech
Average Trading Volume: 6,871
Technical Sentiment Signal: Sell
Current Market Cap: $7.84M
See more insights into NKGN stock on TipRanks’ Stock Analysis page.